Krystal Biotech Inc (KRYS)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | 65,694 | 27,453 | -20,973 | -67,587 | -109,726 | -147,635 | -153,093 | -143,798 | -145,197 | -132,302 | -116,503 | -104,143 | -68,274 | -56,818 | -50,846 | -41,407 | -33,000 | -28,734 | -24,396 | -23,332 |
| Total assets | US$ in thousands | 1,055,840 | 982,318 | 917,658 | 853,296 | 818,355 | 790,350 | 684,026 | 531,847 | 558,450 | 576,379 | 601,324 | 616,874 | 626,295 | 451,095 | 443,556 | 443,018 | 310,844 | 311,451 | 318,145 | 205,131 |
| Operating ROA | 6.22% | 2.79% | -2.29% | -7.92% | -13.41% | -18.68% | -22.38% | -27.04% | -26.00% | -22.95% | -19.37% | -16.88% | -10.90% | -12.60% | -11.46% | -9.35% | -10.62% | -9.23% | -7.67% | -11.37% |
December 31, 2024 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $65,694K ÷ $1,055,840K
= 6.22%
Operating ROA is a key financial ratio that measures a company's ability to generate earnings from its operating activities relative to its total assets. Krystal Biotech Inc's Operating ROA has shown a declining trend over the quarters, indicating a decreasing efficiency in utilizing its assets to generate operating income. The Operating ROA was negative for most of the periods, suggesting that the company was not effectively generating operating profits from its total assets.
However, there was a notable turnaround in the company's performance starting from September 30, 2024, where the Operating ROA turned positive and increased significantly in the subsequent quarters. This positive trend indicates that Krystal Biotech Inc has been able to improve its operational efficiency and generate higher operating income in relation to its total assets during these periods.
Overall, the analysis of Krystal Biotech Inc's Operating ROA reflects a challenging operating environment initially, followed by a significant improvement in operational performance, signaling a rebound in the company's ability to generate operating profits from its assets.
Peer comparison
Dec 31, 2024